Dabigatran etexilate-d13

• UNSPSC Description:

  Dabigatran etexilate-d13 is the deuterium labeled Dabigatran etexilate. Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran. Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation[1].

• Target Antigen:

  Isotope-Labeled Compounds; Thrombin

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Metabolic Enzyme/Protease;Others

• Field of Research:

  Cardiovascular Disease

• Purity:

  98.0

• Solubility:

  10 mM in DMSO

• Smiles:

  CN1C2=CC=C(C(N(C3=CC=CC=N3)CCC(OCC)=O)=O)C=C2N=C1CNC4=CC=C(C=C4)C(NC(OC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=O)=N

• Molecular Weight:

  640.81

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Wienen W, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally activeprodrug, dabigatran etexilate. Thromb Haemost. 2007 Jul;98(1):155-62.|[3]Blair HA, Keating GM. Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation. Drugs. 2017;77(3):331-344.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  2749293-92-1